Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437

Watchlist Manager
Harbin Gloria Pharmaceuticals Co Ltd Logo
Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437
Watchlist
Price: 2.45 CNY 4.26% Market Closed
Market Cap: 5.6B CNY

Harbin Gloria Pharmaceuticals Co Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Harbin Gloria Pharmaceuticals Co Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437
Total Current Liabilities
ÂĄ837.7m
CAGR 3-Years
-34%
CAGR 5-Years
-28%
CAGR 10-Years
-2%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Current Liabilities
ÂĄ6.9B
CAGR 3-Years
37%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Current Liabilities
ÂĄ2.5B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
26%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Current Liabilities
ÂĄ4.8B
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
20%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Current Liabilities
ÂĄ13.8B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
14%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Current Liabilities
ÂĄ1.1B
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Harbin Gloria Pharmaceuticals Co Ltd
Glance View

Market Cap
5.6B CNY
Industry
Pharmaceuticals

Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines. The company is headquartered in Beijing, Beijing and currently employs 4,769 full-time employees. The company went IPO on 2010-06-23. The firm's products include cardiovascular and cerebrovascular drugs, orthopedic drugs, nutritional drugs, anti-infective drugs, immune-enhancing drugs, diabetes drugs, antineoplastic drugs and electrolytes drugs. The firm is also engaged in the agency, research and development of pharmaceuticals, the provision of clinical services and financial investment business. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
2.73 CNY
Undervaluation 10%
Intrinsic Value
Price

See Also

What is Harbin Gloria Pharmaceuticals Co Ltd's Total Current Liabilities?
Total Current Liabilities
837.7m CNY

Based on the financial report for Sep 30, 2024, Harbin Gloria Pharmaceuticals Co Ltd's Total Current Liabilities amounts to 837.7m CNY.

What is Harbin Gloria Pharmaceuticals Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
-2%

Over the last year, the Total Current Liabilities growth was -50%. The average annual Total Current Liabilities growth rates for Harbin Gloria Pharmaceuticals Co Ltd have been -34% over the past three years , -28% over the past five years , and -2% over the past ten years .

Back to Top